Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illumina, Inc.

http://www.illumina.com

Latest From Illumina, Inc.

Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter

Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

Companies Deals

Financing: Q3 Roundup Shows Fall In Device Company Activity But A Rise In IVDs

During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Companies Financing

Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

In Vitro Diagnostics Cancer

Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021

Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.

Financing In Vitro Diagnostics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • GenoLogics Life Sciences Software
    • GRAIL Inc.
    • Myraqa
    • Verinata Health
    • Illumina Ventures
UsernamePublicRestriction

Register